NCT Research

NCT Clinical Cancer Program in Genitourinary Tumors

Expertise

Clinical and translational research activities focus on first-in-man trials, MRI-guided transurethral ultrasound therapy of prostate cancer, the DKH approved risk-adapted PSA screening trial (Probase; Arsov Eur Urol 2013), PSMA ligand-based PET imaging and a new platform for transperineal MRI-targeted TRUS fusion-guided biopsy (Afshar-Oromieh Eur J Nucl Med Mol Imaging 2013; Hadaschik J Urol 2011; Kuru J Urol 2013; Moore Eur Urol 2013; Roethke Eur Urol 2013). Molecular biomarker research projects are conducted in collaboration with DKFZ and HUMS (Brase Int J Cancer 2011; Cuevas Cancer Res 2013; Weischenfeldt Cancer Cell 2013; Weissinger Mol Cancer 2013). DKFZ coordinates the ICGC prostate cancer project and NCT POP provides high-throughput analysis for clinical projects in urooncology. The combined goal is to use predictive biomarkers, focal therapy, imaging, and MRI-targeted biopsy for improved treatment of patients with urogenital cancers.

Urological Tumors
 

  1. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beißbarth T, Kuner R, Sültmann H: Circulating micro RNAs are correlated with tumor progression in prostate cancer. International Journal of Cancer 128 (3), 608-616, 2011.
  2. Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, Huber J, Zogal P, Teber D, Pahernik S, Roethke M, Zamecnik P, Roth W, Sakas G, Schlemmer HP, Hohenfellner M.A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol. 2011 Dec;186(6):2214-20
  3. Weischenfeldt, J.*, Simon, R.*, Feuerbach, L.*, Schlangen, K.*, Weichenhan, D.*, Minner, S.*, Wuttig, D.*, Warnatz, H.-J., Stehr, H., Rausch, T., Jaeger, N., Gu,L., Bogatyrova, O., Stuetz, A.M., Claus, R., Eils, J., Eils, R., Gerhaeuser, C., Huang,P.-H., Hutter, B., Kabbe, R., Lawerenz, C., Radomski, S., Bartholomae, C.C., Fälth, M., Gade, S., Schmidt, M., Amschler, N., Hass, T., Galal, R., Gjoni, J., Kuner, R., Baer, C., Masser, S., von Kalle, C., Zichner, T., Benes, V., Raeder, B., Mader, M., Amstislavskiy, V., Avci, M., Lehrach, H., Parkhomchuk, D., Sultan, M., Burkhardt, L., Graefen, M., Huland, H., Kluth, M., Krohn, A., Sirma, H., Stumm, L., Steurer, S., Grupp, K., Sültmann, H.*, Sauter, G.*, Plass, C.*, Brors, B.*, Yaspo, M.-L.*, Korbel, J.O.*, Schlomm, T.* (* shared first / senior authorship): Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013 Feb 11;23(2):159-70.
  4. Weissinger D, Tagscherer KE, Macher-Göppinger S, Haferkamp A, Wagener N, Roth W. The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Molecular Cancer 2013, in press
  5. Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. Eur Urol. 2013 Jul 10. doi:pii: S0302-2838(13)00663-5. 10.1016/j.eururo.2013.06.048. [Epub ahead of print]